PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of jexpmedHomeThe Rockefeller University PressEditorsContactInstructions for AuthorsThis issue
 
J Exp Med. 1988 February 1; 167(2): 353–371.
PMCID: PMC2188841

The E mu-myc transgenic mouse. A model for high-incidence spontaneous lymphoma and leukemia of early B cells

Abstract

Mice transgenic for a c-myc gene driven by the IgH enhancer (E mu-myc) were shown to almost invariably develop lymphomas, 90% succumbing in the first 5 mo of life. The tumors typically presented as rapidly progressive lymphadenopathy with thymic involvement and were highly malignant by transplantation assay. Morphologically, they were lymphoblastic lymphomas, usually accompanied by lymphoid leukemia and granulocytosis, and were distinct from the tumors that arose much later in 37% of nontransgenic mice of the same (C57BL/6 x SJL)F2 genetic background. Cell-surface markers on 31 E mu-myc tumors identified 52% as pre-B lymphomas, 29% as mixed pre-B and B lymphomas, and 19% as B lymphomas. The tumors appeared to arise at random from a population of pre-B cells expanded by constitutive expression of the myc transgene. A majority of the animals initiated malignancy at the rate of 17% per week. The rate at which the cycling, benign pre-B cells spontaneously convert to malignancy was estimated to about 10(-10) per cell per generation. A transient leukocytosis identified in young E mu-myc mice was developed into a rapid assay for inheritance of the transgene.

Full Text

The Full Text of this article is available as a PDF (1.5M).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Cory S. Activation of cellular oncogenes in hemopoietic cells by chromosome translocation. Adv Cancer Res. 1986;47:189–234. [PubMed]
  • Kelly K, Siebenlist U. The regulation and expression of c-myc in normal and malignant cells. Annu Rev Immunol. 1986;4:317–338. [PubMed]
  • Cole MD. The myc oncogene: its role in transformation and differentiation. Annu Rev Genet. 1986;20:361–384. [PubMed]
  • Studzinski GP, Brelvi ZS, Feldman SC, Watt RA. Participation of c-myc protein in DNA synthesis of human cells. Science. 1986 Oct 24;234(4775):467–470. [PubMed]
  • Iguchi-Ariga SM, Itani T, Kiji Y, Ariga H. Possible function of the c-myc product: promotion of cellular DNA replication. EMBO J. 1987 Aug;6(8):2365–2371. [PubMed]
  • Kelly K, Cochran BH, Stiles CD, Leder P. Cell-specific regulation of the c-myc gene by lymphocyte mitogens and platelet-derived growth factor. Cell. 1983 Dec;35(3 Pt 2):603–610. [PubMed]
  • Palmiter RD, Brinster RL. Germ-line transformation of mice. Annu Rev Genet. 1986;20:465–499. [PubMed]
  • Stewart TA, Pattengale PK, Leder P. Spontaneous mammary adenocarcinomas in transgenic mice that carry and express MTV/myc fusion genes. Cell. 1984 Oct;38(3):627–637. [PubMed]
  • Leder A, Pattengale PK, Kuo A, Stewart TA, Leder P. Consequences of widespread deregulation of the c-myc gene in transgenic mice: multiple neoplasms and normal development. Cell. 1986 May 23;45(4):485–495. [PubMed]
  • Alexander WS, Schrader JW, Adams JM. Expression of the c-myc oncogene under control of an immunoglobulin enhancer in E mu-myc transgenic mice. Mol Cell Biol. 1987 Apr;7(4):1436–1444. [PMC free article] [PubMed]
  • Langdon WY, Harris AW, Cory S, Adams JM. The c-myc oncogene perturbs B lymphocyte development in E-mu-myc transgenic mice. Cell. 1986 Oct 10;47(1):11–18. [PubMed]
  • Adams JM, Harris AW, Pinkert CA, Corcoran LM, Alexander WS, Cory S, Palmiter RD, Brinster RL. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature. 1985 Dec 12;318(6046):533–538. [PubMed]
  • Brinster RL, Chen HY, Trumbauer M, Senear AW, Warren R, Palmiter RD. Somatic expression of herpes thymidine kinase in mice following injection of a fusion gene into eggs. Cell. 1981 Nov;27(1 Pt 2):223–231. [PubMed]
  • Brinster RL, Chen HY, Trumbauer ME, Yagle MK, Palmiter RD. Factors affecting the efficiency of introducing foreign DNA into mice by microinjecting eggs. Proc Natl Acad Sci U S A. 1985 Jul;82(13):4438–4442. [PubMed]
  • Pattengale PK, Taylor CR. Experimental models of lymphoproliferative disease. The mouse as a model for human non-Hodgkin's lymphomas and related leukemias. Am J Pathol. 1983 Nov;113(2):237–265. [PubMed]
  • Dunn TB, Deringer MK. Reticulum cell neoplasm, type B, or the "Hodgkin's-like lesion" of the mouse. J Natl Cancer Inst. 1968 Apr;40(4):771–821. [PubMed]
  • McKenzie IF, Potter T. Murine lymphocyte surface antigens. Adv Immunol. 1979;27:179–338. [PubMed]
  • Pattengale PK, Taylor CR, Twomey P, Hill S, Jonasson J, Beardsley T, Haas M. Immunopathology of B-cell lymphomas induced in C57BL/6 mice by dualtropic murine leukemia virus (MuLV). Am J Pathol. 1982 Jun;107(3):362–377. [PubMed]
  • Strober S, Gronowicz ES, Knapp MR, Slavin S, Vitetta ES, Warnke RA, Kotzin B, Schröder J. Immunobiology of a spontaneous murine B cell leukemia (BCL1). Immunol Rev. 1979;48:169–195. [PubMed]
  • Abelson HT, Rabstein LS. Lymphosarcoma: virus-induced thymic-independent disease in mice. Cancer Res. 1970 Aug;30(8):2213–2222. [PubMed]
  • Siegler R, Zajdel S. Pathogenesis of Abelson-virus-induced murine leukemia. J Natl Cancer Inst. 1972 Jan;48(1):189–218. [PubMed]
  • Opstelten D, Osmond DG. Regulation of pre-B cell proliferation in bone marrow: immunofluorescence stathmokinetic studies of cytoplasmic mu chain-bearing cells in anti-IgM-treated mice, hematologically deficient mutant mice and mice given sheep red blood cells. Eur J Immunol. 1985 Jun;15(6):599–605. [PubMed]
  • DUNN TB, MOLONEY JB, GREEN AW, ARNOLD B. Pathogenesis of a virus-induced leukemia in mice. J Natl Cancer Inst. 1961 Jan;26:189–221. [PubMed]
  • Alt F, Rosenberg N, Lewis S, Thomas E, Baltimore D. Organization and reorganization of immunoglobulin genes in A-MULV-transformed cells: rearrangement of heavy but not light chain genes. Cell. 1981 Dec;27(2 Pt 1):381–390. [PubMed]
  • Sugiyama H, Akira S, Yoshida N, Kishimoto S, Yamamura Y, Kincade P, Honjo T, Kishimoto T. Relationship between the rearrangement of immunoglobulin genes, the appearance of a B lymphocyte antigen, and immunoglobulin synthesis in murine pre-B cell lines. J Immunol. 1982 Jun;128(6):2793–2797. [PubMed]
  • Bonavida B. The SJL/J spontaneous reticulum cell sarcoma: new insights in the fields of neoantigens, host-tumor interactions, and regulation of tumor growth. Adv Cancer Res. 1983;38:1–22. [PubMed]
  • Brown PH, Thorbecke GJ. Characterization of the molecules on SJL/J lymphomas which stimulate syngeneic T cells. J Immunol. 1985 Nov;135(5):3572–3580. [PubMed]
  • McIntire KR, Law LW. Abnormal serum immunoglobulins occurring with reticular neoplasms in a inbred strain of mouse. J Natl Cancer Inst. 1967 Dec;39(6):1197–1211. [PubMed]
  • Bubbers JE. Identification and linkage analyses of a gene, Rcs-1, suppressing spontaneous SJL/J lymphoma expression. J Natl Cancer Inst. 1984 Feb;72(2):441–446. [PubMed]
  • Greaves MF. Differentiation-linked leukemogenesis in lymphocytes. Science. 1986 Nov 7;234(4777):697–704. [PubMed]
  • Greaves MF, Chan LC. Is spontaneous mutation the major 'cause' of childhood acute lymphoblastic leukaemia? Br J Haematol. 1986 Sep;64(1):1–13. [PubMed]

Articles from The Journal of Experimental Medicine are provided here courtesy of The Rockefeller University Press